These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34904813)

  • 61. Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy.
    Li L; Kumar AK; Hu Z; Guo Z
    Curr Med Chem; 2021; 28(5):963-985. PubMed ID: 32091326
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Strategies for targeting the DNA damage response for cancer therapeutics.
    Zhang D; Wang HB; Brinkman KL; Han SX; Xu B
    Chin J Cancer; 2012 Aug; 31(8):359-63. PubMed ID: 22704491
    [TBL] [Abstract][Full Text] [Related]  

  • 64. DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies.
    Kwok M; Agathanggelou A; Stankovic T
    Blood; 2024 May; 143(21):2123-2144. PubMed ID: 38457665
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Impairment of DNA damage response and cancer].
    Rancoule C; Vallard A; Guy JB; Espenel S; Sauvaigo S; Rodriguez-Lafrasse C; Magné N
    Bull Cancer; 2017 Nov; 104(11):962-970. PubMed ID: 29132683
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.
    Zhang W; Zhang L; Jiang H; Li Y; Wang S; Wang Q
    Aging (Albany NY); 2021 Nov; 13(21):24136-24154. PubMed ID: 34747718
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
    Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
    Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The DNA damage response pathway in normal hematopoiesis and malignancies.
    Delia D; Mizutani S
    Int J Hematol; 2017 Sep; 106(3):328-334. PubMed ID: 28707218
    [TBL] [Abstract][Full Text] [Related]  

  • 69. DNA Repair: Translation to the Clinic.
    Minten EV; Yu DS
    Clin Oncol (R Coll Radiol); 2019 May; 31(5):303-310. PubMed ID: 30876709
    [TBL] [Abstract][Full Text] [Related]  

  • 70. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors.
    Riabinska A; Daheim M; Herter-Sprie GS; Winkler J; Fritz C; Hallek M; Thomas RK; Kreuzer KA; Frenzel LP; Monfared P; Martins-Boucas J; Chen S; Reinhardt HC
    Sci Transl Med; 2013 Jun; 5(189):189ra78. PubMed ID: 23761041
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis.
    Farg MA; Konopka A; Soo KY; Ito D; Atkin JD
    Hum Mol Genet; 2017 Aug; 26(15):2882-2896. PubMed ID: 28481984
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase.
    Campillo-Marcos I; Lazo PA
    J Exp Clin Cancer Res; 2019 May; 38(1):203. PubMed ID: 31101118
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents.
    Martorana F; Da Silva LA; Sessa C; Colombo I
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205700
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Targeting DNA damage response in cancer therapy.
    Hosoya N; Miyagawa K
    Cancer Sci; 2014 Apr; 105(4):370-88. PubMed ID: 24484288
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
    Wengner AM; Siemeister G; Lücking U; Lefranc J; Wortmann L; Lienau P; Bader B; Bömer U; Moosmayer D; Eberspächer U; Golfier S; Schatz CA; Baumgart SJ; Haendler B; Lejeune P; Schlicker A; von Nussbaum F; Brands M; Ziegelbauer K; Mumberg D
    Mol Cancer Ther; 2020 Jan; 19(1):26-38. PubMed ID: 31582533
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeting the DNA Damage Response in Cancer.
    O'Connor MJ
    Mol Cell; 2015 Nov; 60(4):547-60. PubMed ID: 26590714
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Analysis of irradiation-induced repair foci in mouse embryonic stem cells].
    Suvorova II; Pospelov VA
    Tsitologiia; 2014; 56(5):340-5. PubMed ID: 25696973
    [TBL] [Abstract][Full Text] [Related]  

  • 79. DNA damage response--a double-edged sword in cancer prevention and cancer therapy.
    Tian H; Gao Z; Li H; Zhang B; Wang G; Zhang Q; Pei D; Zheng J
    Cancer Lett; 2015 Mar; 358(1):8-16. PubMed ID: 25528631
    [TBL] [Abstract][Full Text] [Related]  

  • 80. DNA damage response and repair in pancreatic cancer development and therapy.
    Rahnamay Farnood P; Danesh Pazhooh R; Asemi Z; Yousefi B
    DNA Repair (Amst); 2021 Jul; 103():103116. PubMed ID: 33882393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.